{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:14:39Z","timestamp":1779916479688,"version":"3.53.1"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T00:00:00Z","timestamp":1462147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Rituximab pharmacokinetics are affected by gender, age and weight and can affect outcomes in aggressive B cell lymphoma. Less is known about the pharmacokinetics of rituximab in indolent B cell lymphoma (<jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>). We analysed the effects of gender, age, weight and body surface area on the outcomes of 303 patients treated with first line rituximab\u2010based regimens for <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>. The patients were divided into 3 treatment cohorts: rituximab only, rituximab\u00a0+\u00a0chemotherapy (R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content>) and R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content> followed by rituximab maintenance; furthermore, each cohort was subdivided as follicular (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>) or non\u2010<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, based on histology. Older males and patients with higher weight had worse outcomes when treated with R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content>, probably due to faster rituximab clearance. Our results concur with studies of R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>. As this effect was not observed in patients treated with rituximab alone or R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content> followed by rituximab maintenance, we hypothesize that higher rituximab levels reached with weekly rituximab and\/or prolonged exposure achieved with maintenance therapy exceed the therapeutic threshold, even with faster clearance, which nullifies the negative effect of higher weight and male gender. In conclusion, under current practices, a subset of patients with <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>, i.e., <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> treated with R\u2010<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content>, may be sub\u2010optimally dosed with rituximab.<\/jats:p>","DOI":"10.1111\/bjh.14114","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T16:28:17Z","timestamp":1462206497000},"page":"721-729","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is rituximab sub\u2010optimally dosed in indolent B cell lymphoma?"],"prefix":"10.1111","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Rouphail","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Jia","sequence":"additional","affiliation":[{"name":"Quantitative Health Sciences Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad L.","family":"Pohlman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_7_4_1","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1851"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121453"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.26008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt594"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.059246"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.327"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380949"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu208"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.12.033"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.6861"},{"issue":"15","key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/jco.2014.32.15_suppl.8501","article-title":"Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20\u00a0+\u00a0 B\u2010cell lymphomas: results from the SEXIE\u2010R\u2010CHOP\u201014 trial of the DSHNHL","volume":"32","author":"Pfreundschuh M.","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01541.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_27_1","first-page":"Cd003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma","volume":"4","author":"Schulz H.","year":"2007","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e13108"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:57:31Z","timestamp":1696251451000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/bjh.14114"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14114","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,2]]},"assertion":[{"value":"2015-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}